Structure-Based Virtual Screening Accelerates GPCR Drug Discovery.

Virtual ligand screening (VLS) against high-resolution structures of G-protein-coupled receptors (GPCRs) is likely to become the next-generation drug design approach of choice. Stein and colleagues recently demonstrated the feasibility of such an approach by discovering novel chemical scaffolds for the melatonin MT1 receptor and compounds with unique in vivo activities.